Results 201 to 210 of about 90,574 (284)
Classification of tau status with machine learning models in amyloid‐positive cohorts
Abstract INTRODUCTION Although tau positron emission tomography (PET) imaging is effective for staging tau pathology, it is limited clinically by cost and availability. Machine learning models based on magnetic resonance imaging (MRI)– and amyloid PET–derived features may serve as useful screening tools for tau pathology.
Yun‐Chi Lin +4 more
wiley +1 more source
Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa +5 more
wiley +1 more source
Dataset of typical terminal lake and surrounding oasis outlines in arid/semi-arid endorheic basins based on remote sensing data. [PDF]
Sun Z +6 more
europepmc +1 more source
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel +9 more
wiley +1 more source
Mapping and predicting groundwater accumulations using remote sensing and aeromagnetic data: a case study from Bahariya Oasis, Western Desert, Egypt. [PDF]
El-Badrawy HT +4 more
europepmc +1 more source
Artificial intelligence techniques for classification of Alzheimer's disease using neuroimaging data: a review. [PDF]
Nibila Y, Sivagami M.
europepmc +1 more source
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
ABSTRACT Objective This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA‐approved OMMs.
Ariana M. Chao +5 more
wiley +1 more source

